Healthcare Oversold Stocks: TearLab Corp (NASDAQ:TEAR), Derma Sciences (NASDAQ:DSCI), Uniqure NV (NASDAQ:QURE), Biocept Inc. (NASDAQ:BIOC)

TearLab Corporation (NASDAQ:TEAR) expects to announce its Q1 2014 financial results after market closes on Thursday May 8, 2014. TearLab Corp (NASDAQ:TEAR) shares after opening at $4.95 moved to $5.05 on last trade day and at the end of the day closed at $4.63. Company price to sales ratio in past twelve months was calculated as 10.64 and price to cash ratio as 4.11. TearLab Corp (NASDAQ:TEAR) showed a negative weekly performance of -21.92%.

Derma Sciences Inc. (NASDAQ:DSCI) Net loss was $5.4 million, or $0.31 per share, compared with a net loss of $3.7 million, or $0.27 per share, in the prior-year fourth quarter. Derma Sciences Inc. (NASDAQ:DSCI) shares fell -2.38% in last trading session and ended the day on $9.43. DSCI return on equity ratio is recorded as -28.40% and its return on assets is -25.10%. Derma Sciences Inc. (NASDAQ:DSCI) yearly performance is -20.08%.

U.S.-listed shares of Netherlands-based pharmaceutical company Uniqure (NASDAQ:QURE) are rising after Baxter International (BAX) acquired Chatham Therapeutics, which is developing gene therapy treatments intended for patients with hemophilia. Uniqure NV (NASDAQ:QURE) shares moved down -1.15% in last trading session and was closed at $9.00, while trading in range of $8.51 – $9.10. Uniqure NV (NASDAQ:QURE) year to date (YTD) performance is -38.40%.

Biocept Inc. (NASDAQ:BIOC) Revenues were approximately $134,000 for the year ended December 31, 2013, compared with approximately $109,000 for the year ended December 31, 2012, an increase of approximately $25,000, or 23%. Biocept Inc. (NASDAQ:BIOC) weekly performance is -22.54%. On last trading day company shares ended up $4.95. Biocept Inc. (NASDAQ:BIOC) distance from 50-day simple moving average (SMA50) is -37.61%.